EE+ POEM Archive
Linagliptin does not increase (or decrease) risk of adverse CVD outcomes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Linagliptin Does Not Increase (or Decrease) Risk of Adverse CVD Outcomes." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314679/0/Linagliptin_does_not_increase__or_decrease__risk_of_adverse_CVD_outcomes.
Linagliptin does not increase (or decrease) risk of adverse CVD outcomes. In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314679/0/Linagliptin_does_not_increase__or_decrease__risk_of_adverse_CVD_outcomes. Accessed April 19, 2024.
Linagliptin does not increase (or decrease) risk of adverse CVD outcomes. (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314679/0/Linagliptin_does_not_increase__or_decrease__risk_of_adverse_CVD_outcomes
Linagliptin Does Not Increase (or Decrease) Risk of Adverse CVD Outcomes [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314679/0/Linagliptin_does_not_increase__or_decrease__risk_of_adverse_CVD_outcomes.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Linagliptin does not increase (or decrease) risk of adverse CVD outcomes
ID - 1314679
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314679/0/Linagliptin_does_not_increase__or_decrease__risk_of_adverse_CVD_outcomes
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
